Evidence map›Paper›PMID 31608625›Full record

ArticleBiochemistry2020

Synthesis of 3-

Vijay Manohar Dhurandhare, Vijayakanth Pagadala, Andreia Ferreira, Louis De Muynck, Jian Liu

Open access · greenAbstract read
In one paragraph

Article in Biochemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. UtilizingAmerican journal of physiology. Cell physiology · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Increased 3-Science advances · 2023
    Article
  8. Article
  9. Emerging chemical and biochemical tools for studying 3-American journal of physiology. Cell physiology · 2022
    Review
  10. Analysis of 3-Analytical chemistry · 2022
    Article
  11. Article
  12. Article
  13. Synthesis of 3-ACS chemical biology · 2021
    Article
  14. Review
  15. ZNF263 is a transcriptional regulator of heparin and heparan sulfate biosynthesis.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  16. Utility of AuthenticProteoglycan research
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Vijay Manohar DhurandhareDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
Vijayakanth PagadalaGlycan Therapeutics, LLC, 617 Hutton Street, Raleigh, North Carolina 27606, United States.
Andreia FerreiraDepartment of Neuroscience, Janssen Research & Development, Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse, Belgium.
Louis De MuynckDepartment of Neuroscience, Janssen Research & Development, Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse, Belgium.
Jian LiuDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0001-8552-1400
Janssen (Belgium) · BEUniversity of North Carolina at Chapel Hill · US

Funding

In vitro synthesis of recombinant heparan sulfateR01HL094463 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LIU, JIAN, PAWLINSKI, RAFAL L · 2009 to 2021
$5.2M
Development of dekaparin to replace animal-sourced heparinR44HL139187 · NHLBI · GLYCAN THERAPEUTICS CORPORATION · PI PAGADALA, VIJAYAKANTH · 2019 to 2025
$4.2M
Diverse Heparan Sulfate Oligosaccharide Libraries For Understanding and Therapeutically Manipulating GlycosaminoglycansR44GM134738 · NIGMS · GLYCAN THERAPEUTICS CORPORATION · PI PAGADALA, VIJAYAKANTH · 2019 to 2021
$3.2M
Synthesis and Pharmacological Evaluation of Homogenous Ultra-Low Molecular Weight HeparinsR01HL144970 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LIU, JIAN · 2019 to 2021
$946k
Developing Heparan Sulfate Glycan ArrayR41GM123792 · NIGMS · GLYCAN THERAPEUTICS CORPORATION · PI LIU, JIAN · 2017 to 2018
$297k
NHLBI NIH HHS R01 HL094463NHLBI NIH HHS R01 HL144970NHLBI NIH HHS R44 HL139187NIGMS NIH HHS R41 GM123792NIGMS NIH HHS R44 GM134738
6 · The paper itself

Abstract

3-

Indexed as

Chemistry Techniques, SyntheticDisaccharidesHeparan SulfateReference StandardsDisaccharidesHeparan Sulfate

Identifiers

PMID31608625
PMCPMC7269455
OpenAlexW2980812496

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.